Recursion Pharmaceuticals (NASDAQ:RXRX) reported updated clinical data for its investigational treatment for familial ...
Zacks Investment Research on MSN
Recursion's Q3 earnings beat estimates on Sanofi milestone revenues
Recursion Pharmaceuticals RXRX reported a loss of 22 cents per share in the third quarter of 2026, narrower than the Zacks ...
Altitude Lab will relocate its accelerator and startup community to Portal Innovations at Woodbine Labs, combining Utah's established biotech accelerator with new laboratory infrastructure, graduate ...
President and Chief Executive Officer - Najat Khan ...
Recursion Q3 2026 earnings: clinical wins for REC-4881 and REC-1245, Sanofi progress, and cash runway to 2029.
The young people in those streets did not come out of nowhere. The last 20 years did real damage.
Recursion said it expects to launch its first registrational trial in the second half of this year for its lead candidate REC-4881 based on talks with the FDA, after the oral familial adenomatous ...
New Phase 2 REC-4881 data presented at CGA-IGC in an expanded adult population aged 18 years and older show deep, durable polyp burden reductions in FAP, with activity throughout the GI tract and in ...
The generosity of strangers has long powered online communities. Spaces like Stack Overflow, GitHub, curl, OpenSSL, Wikipedia ...
Tech Times on MSN
UK startup backed by Patrick Collison exits stealth to generate drug discovery data from physics
UK startup Potential Sciences exits stealth with eight-figure UK government seed to fix AI drug discovery's data bottleneck ...
A $10 million Sanofi milestone drove revenue 258% higher year over year, beating expectations and showing the AI platform ...
Improvement" Take on a Life of Its Own?"If we keep having an AI improve itself, wouldn't explosive evolution (Recursive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results